Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832

Watchlist Manager
Shenzhen New Industries Biomedical Engineering Co Ltd Logo
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
Watchlist
Price: 64.91 CNY -2.21%
Market Cap: 51B CNY
Have any thoughts about
Shenzhen New Industries Biomedical Engineering Co Ltd?
Write Note

Gross Margin
Shenzhen New Industries Biomedical Engineering Co Ltd

72.5%
Current
71%
Average
47.1%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
72.5%
=
Gross Profit
3.2B
/
Revenue
4.4B

Gross Margin Across Competitors

Country CN
Market Cap 51B CNY
Gross Margin
72%
Country JP
Market Cap 7T JPY
Gross Margin
86%
Country CH
Market Cap 38.2B CHF
Gross Margin
55%
Country DK
Market Cap 177.1B DKK
Gross Margin
68%
Country US
Market Cap 16.3B USD
Gross Margin
70%
Country KR
Market Cap 10.3T KRW
Gross Margin
15%
Country US
Market Cap 6.7B USD
Gross Margin
65%
Country CA
Market Cap 6.3B USD
Gross Margin
61%
Country UK
Market Cap 4.6B GBP
Gross Margin
56%
Country US
Market Cap 5.6B USD
Gross Margin
47%
Country CH
Market Cap 4.7B CHF
Gross Margin
35%
No Stocks Found

Shenzhen New Industries Biomedical Engineering Co Ltd
Glance View

Market Cap
51B CNY
Industry
Health Care

Amidst the sprawling innovation-centric landscape of Shenzhen, Shenzhen New Industries Biomedical Engineering Co., Ltd., often abbreviated as SNIBE, stands out as a beacon in the realm of biotechnology. Founded in 1995, SNIBE has steadily carved out a significant niche in the medical devices industry, particularly in in-vitro diagnostic products. The company has become synonymous with the development, manufacture, and sale of diagnostic reagents and fully automated chemiluminescence immunoassay systems, which have gained widespread recognition in over 150 countries. By focusing on the integration of cutting-edge technology in diagnostic immunoassays, SNIBE ensures that hospitals and laboratories worldwide can attain high accuracy and efficiency in medical testing, while concurrently meeting the growing global demand for advanced diagnostic tools. The financial engine that propels SNIBE is powered by its robust supply chain and diversified product offerings. With its line-up of innovative diagnostic products, the company generates the bulk of its revenue through long-term contracts with health institutions, research centers, and clinical laboratories. These partnerships are augmented by continuous investment in research and development, ensuring a steady flow of novel products capable of addressing pressing medical needs. Additionally, SNIBE’s strategic emphasis on international markets has fortified its revenue streams, allowing it to mitigate risks associated with saturation or volatility in domestic markets. Through its unwavering focus on innovation and strategic expansion, SNIBE not only sustains its financial health but also continually contributes to advancements in global healthcare diagnostics.

Intrinsic Value
88.02 CNY
Undervaluation 26%
Intrinsic Value
Price
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
72.5%
=
Gross Profit
3.2B
/
Revenue
4.4B
What is the Gross Margin of Shenzhen New Industries Biomedical Engineering Co Ltd?

Based on Shenzhen New Industries Biomedical Engineering Co Ltd's most recent financial statements, the company has Gross Margin of 72.5%.